DOCSLIB.ORG

For a Healthier Tomorrow

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For a Healthier Tomorrow Building Momentum for a Healthier Tomorrow Annual Report | 2019-20 Mr. Samprada Singh 2nd May, 1930 to 27th July, 2019 Remembering Our Founder & Chairman Emeritus A true visionary and an impactful leader, Mr. Samprada Singh’s story and life are full of wonderful lessons of courage, resolve, hard work and indomitable willpower. He overcame the financial difficulties that his familyad h to face to become the first graduate from his village in Bihar. He then braved the challenges of venturing into newer avenues – from selling umbrellas to opening a medical store to setting up his own pharmaceutical distribution company in the late 50s. Our beloved founder was determined to use his vast knowledge and deep understanding of the Indian pharmaceutical industry garnered over nearly two decades to champion change in an era when the market was dominated by international companies. The bold step came in 1973 with his decision to establish Alkem Laboratories. Guided by his visionary leadership and extraordinary business acumen, our Company not only competed successfully with global giants but also emerged as one of India’s largest pharmaceutical companies. Mr. Samprada Singh’s imprint extended well beyond our business. His guiding principle of striving for excellence in all that we do has been an inspiration to all who had the privilege of knowing him. His life is a testimony to the fact that with zeal, determination and hard work, no dream is unattainable. While he is physically not present amongst us today, his life, achievements and deep-rooted virtues will continue to guide Alkemites to scale new heights. We stand committed to his vision and building on his legacy. Contents Corporate Overview Financial Statements 03 Corporate Information Standalone 04 About Alkem 94 Independent Auditor’s Report 06 Building Momentum in Biologics 102 Balance Sheet 07 Building Momentum for International Business 103 Statement of Profit and Loss 08 Chairman’s Message 104 Statement of Changes in Equity 10 Message from the MD’s Desk 105 Statement of Cash Flow 12 Board Profile 107 Notes 14 Key Financial Highlights 16 Building Momentum for a Healthier Workplace Consolidated 19 Building Momentum for Sustained Change 155 Independent Auditor’s Report 21 Together Against COVID-19 for a Healthier World 162 Balance Sheet 163 Statement of Profit and Loss 164 Statement of Changes in Equity 166 Statement of Cash Flow 168 Notes Statutory Reports 229 Notice 22 Management Discussion & Analysis 40 Directors’ Report 69 Corporate Governance Report 86 Business Responsibility Report Key Figures - FY 2019-20 ₹ 83,444 Mn ₹ 14,734 Mn ₹ 11,271 Mn ₹ 94.26 Revenue from EBITDA Profit After Tax Earnings Per Share Operations To view the online version of this report or for other information, log on to: www.alkemlabs.com 03-21 Corporate Overview 22-93 Statutory Reports 94-228 Financial Statements Corporate Information Board of Directors Registered Office Mr. Basudeo N. Singh Alkem House, Senapati Bapat Marg, Lower Parel, Executive Chairman Mumbai - 400 013, Maharashtra, India ClN: L00305MH1973PLC174201 Mr. Sandeep Singh Telephone: +91 22 3982 9999 Managing Director Fax: +91 22 2495 2955 Mr. Dhananjay Kumar Singh Website: www.alkemlabs.com Joint Managing Director Email: [email protected] Mr. Balmiki Prasad Singh Executive Director Registrar & Share Transfer Agents Mr. Mritunjay Kumar Singh M/s Link Intime India Private Limited Executive Director Unit: Alkem Laboratories Limited C-101, 247 Park, L.B.S. Marg, Mr. Sarvesh Singh Vikhroli (West), Mumbai - 400 083 Executive Director Telephone: +91 22 4918 6270 Mr. Arun Kumar Purwar Fax: +91 22 4918 6060 Independent Director E-mail id: [email protected] Website: www.linkintime.co.in Mr. Ranjal Laxmana Shenoy Independent Director Plant Locations Mr. Narendra Kumar Aneja Independent Director 1. Unit I & II, Daman, India 2. Mandva, Gujarat, India Ms. Sangeeta Singh 3. Ankleshwar, Gujarat, India Independent Director 4. Unit I & II, Baddi, Himachal Pradesh, India Ms. Sudha Ravi 5. Kumrek, East Sikkim, India Independent Director 6. Alkem Health Science, (Unit of the Company) Unit I, II & III, Samardung, South Sikkim, India Dr. Dheeraj Sharma 7. California, U.S.A. Independent Director 8. Missouri, U.S.A. 9. Indchemie Health Specialities Private Limited, Somnath, Key Managerial Personnel Daman, India 10. Indchemie Health Specialities Private Limited, Amaliya, Mr. Rajesh Dubey Daman, India President - Finance and Chief Financial Officer 11. Indchemie Health Specialities Private Limited, Baddi, Mr. Manish Narang Himachal Pradesh, India President – Legal, Company Secretary and Compliance Officer 12. Unit I & II, Indchemie Health Specialities Private Limited, Kumrek, East Sikkim, India 13. Cachet Pharmaceuticals Private Limited, Baddi, Auditors Himachal Pradesh, India M/s. B S R & Co. LLP, Chartered Accountants 14. Alkem Labs Ltd, Unit 5, South Sikkim, India 15. Alkem Labs Ltd., S.E.Z., Indore, Madhya Pradesh, India Bankers 16. Enzene Biosciences Limited, Chakan, Pune, Maharashtra, India SBI Bank Syndicate Bank HDFC Bank Barclays Bank Major Research Centres Citi Bank IDBI Bank 1. R&D Centre, MIDC, Taloja, Maharashtra, India BNP Paribas Bank ICICI Bank 2. R&D Centre, Mandva, Gujarat, India DBS Bank MUFJ Bank (Bank of Tokyo) 3. Enzene Biosciences Limited, T-Block, MIDC, Bhosari, Yes Bank Emirates NBD Pune, Maharashtra, India Mizuho Bank Firstrand Bank 4. Enzene Biosciences Limited, MIDC, Bhosari, Kotak Mahindra Bank Shinhan Bank Pimpri-Chinchwad, Pune, Maharashtra, India Saraswat Co-op Bank Federal Bank 5. S&B Pharma Inc., California, U.S.A. HSBC Bank HDFC Limited (NBFC) 6. S&B Pharma Inc., Missouri, U.S.A. Axis Bank Alkem Laboratories Ltd. 3 About Alkem Leading Today On Course for Tomorrow Headquartered in Mumbai, Alkem Laboratories is one of India’s Making a difference to patients’ lives is an intrinsic element foremost global pharmaceutical company. The Company is of Alkem’s philosophy. Powered by this purpose, the engaged in the development, manufacture and marketing Company pursues R&D with vigour and continues to expand its of pharmaceuticals with operational footprints across 40+ operations both beyond its shores and within. This momentum countries. In India, it has a formidable presence in several for a healthier tomorrow is supported by the Company’s robust therapy segments and consistently features amongst the top ten infrastructure. It has 21 manufacturing facilities and 6 R&D pharmaceutical companies. centres located across India and the US. An extensive pan-India Steered by its industry experience of over four decades, Alkem sales and distribution network, forte in brand building and offers high-quality branded generics, generic drugs, active marketing, a large and talented workforce, and an experienced pharmaceutical ingredients and nutraceuticals. The Company’s management team further reinforce its capabilities. product portfolio features over 800 brands encompassing all major therapeutic segments. Inspiring us Towards Tomorrow To achieve value-driven leadership in the Indian Healthcare Industry and beyond through: Our Vision Quality that is infinite Service that cares Hard work that endures Key Facts About the Company Four decades Successfully ` 278.1 billion 5th 21 6 Incorporated in 1973 completed – More than four Initial Public Market Largest Manufacturing R&D centres decades of experience Offering (IPO) in capitalisation as on pharmaceutical facilities across across India in pharmaceutical December 2015 31st March, 2020* company in India India and US and US industry in terms of market share ** Established India Business # 1 # 3 800+ 10 7 Pan India distribution Anti-Infective Rank in Gastro- Brands in India Brands with annual Brands network with 40+ company in India intestinal and sales of more Feature amongst sales depots / for over 15 years** Analgesic therapy than ` 1 billion** top 100 warehouses and segments in India** pharmaceutical >7,000 stockists brands in India** Fast-growing International Business 40+ US$300+ million 6 >1,100 144 89 Countries Revenues from US USFDA approved Filings across Cumulative ANDA approvals Global presence business facilities in India various Abbreviated New from the US FDA# and US international Drug Applications markets (ANDA) filings with the US FDA# *Source: NSE website **Source: IQVIA data #Includes 2 NDA, as on 31st March, 2020 4 Annual Report 2019-20 03-21 Corporate Overview 22-93 Statutory Reports 94-228 Financial Statements Market-Wise Revenue Segmentation Other international markets ₹ 5,382 Mn US 6.4% revenue India ₹ 21,999 Mn contribution ₹ 56,062 Mn 26.4% revenue contribution 67.2% revenue contribution Map not to scale. For illustrative purposes only. Manufacturing Facilities & Capabilities in India Manufacturing Facilities & Capabilities in the US Location No. of Manufacturing Location No. of Manufacturing Facilities Capabilities Facilities Capabilities Baddi 4 Formulations - Tablets, Injectables, Dry Syrup Sikkim 7 Formulations - Tablets, Injectables, Dry Syrup California 1 Active Pharmaceutical Daman 4 Formulations - Capsules, Tablets, Ingredients (APIs) Injectables, Dry Syrup Mandva 1 Active Pharmaceutical Ingredients (APIs) St. Louis 1 Formulations - Liquids, Nasal Ankleshwar 1 Active Pharmaceutical Ingredients (APIs) (Missouri) Sprays, Semi-solids, Solids Indore 1 Formulations - Capsules, Tablets, Dry Syrup Pune 1 Biosimilars R&D Facilities in India R&D Facilities in the US Location No. of Facilities Location No. of Facilities Taloja 1 California 1 Pune 2 Mandva 1 St.
Load more

Recommended publications
  • Inner 20 Ethical Fund Low
    Tata Ethical Fund (An open ended equity scheme following Shariah principles) As on 30th June 2020 PORTFOLIO No. of Market Value % of No. of Market Value % of INVESTMENT STYLE Company name Company name An equity scheme which invests primarily in equities of Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets Shariah compliant companies and other instrument if Equity & Equity Related Total 49401.57 90.21 Oil allowed under Shariah principles. Auto Oil & Natural Gas Co. 925000 752.49 1.37 INVESTMENT OBJECTIVE Hero Motocorp Ltd. 31300 797.20 1.46 Pesticides To provide medium to long- term capital gains by investing Auto Ancillaries Rallis India Ltd. 502000 1366.95 2.50 in Shariah compliant equity and equity related instruments Wabco India Ltd. 15800 1087.06 1.99 Petroleum Products of well-researched value and growth - oriented companies. Sundram Fasteners Ltd. 267000 999.38 1.83 Bharat Petroleum Corporation Ltd. 435000 1626.90 2.97 Tata Ethical Fund aims to generate medium to long term Amara Raja Batteries Ltd. 116849 759.99 1.39 Castrol India Ltd. 505000 634.79 1.16 capital growth by investing in equity and equity related Cement Pharmaceuticals instruments of shariah compliant companies. Shree Cement Ltd. 3800 875.94 1.60 Alkem Laboratories Ltd. 83000 1965.69 3.59 DATE OF ALLOTMENT Commercial Services Ipca Laboratories Ltd. 93750 1569.75 2.87 May 24,1996 3M India Ltd. 4500 845.79 1.54 Lupin Ltd. 145000 1322.11 2.41 Consumer Durables Software FUND MANAGER Titan Company Ltd. 113000 1073.33 1.96 Tata Consultancy Services Ltd.
    [Show full text]
  • Availability and Regulatory Status of Major Antiretroviral Drugs (September 2009)
    Availability and regulatory status of major antiretroviral drugs (September 2009) Medium price per patient per year (in U$) Suppliers International Preferred 2008 Dosage Nonproprietary Strengths form Lower Upper Name (INN) (adults) Low income Middle Middle Originator Generics income income Aurobindo Pharma Ltd.; Cipla Ltd.; Eastern Surgical Company; Emcure; Hetero Drugs 317 a 370 Ltd.; Laboratorio Elea S.A.C.I.F.y A; Abacavir tablets 300 mg 350 a GlaxoSmithKline (286-370) (353-401) Laborotorios Filaxis Argentina; Laborotorios (313-374) Richmond S.A.C.I.F; Matrix Laboratories Ltd.; Ranbaxy Ltd; Strides Arcolab Ltd. 238 a Matrix, Ranbaxy, Hetero; Cipla; Aurobindo; Tenofovir tablets 300 mg 166 a 207 a Gilead Sciences (238-420) Emcure; Aspen; Strides Arcolab Ltd. (151-207) (177-256) Apotex Mexico (Protein, S.A. de C.V.); Aspen Pharmacare Ltd.; Aurobindo Pharma Ltd.; Cipla Ltd.; Cristalia, productos quimicos 212 a 462 Bristol-Myers farmaceuticos Ltda.; Emcure; Hetero Drugs 100 mg 251 a (187-235) (242-1100) Squibb Ltd.; Laboratorio Dosa S.A; Laborotorios (187-310) Filaxis Argentina; Laborotorios Richmond buffered S.A.C.I.F; Ranbaxy Ltd.; Zhejiang Huahai tablets Pharmaceutical Co., Ltd. 208 b Bristol-Myers Aspen Pharmacare Ltd.; Aurobindo Pharma 150 mg Didanosine (172-244) Squibb Ltd.; Cipla Ltd. Aurobindo Pharma Ltd; Barr Laboratories, Inc; 242 a 238 a 220 Bristol-Myers 200 mg Cipla Ltd.; Laborotorios Richmond S.A.C.I.F; (197-310) (233-794) (217-235) Squibb Macleods Pharmaceuticals Ltd.; Ranbaxy Ltd.; 242 a 238 a 220 Bristol-Myers 200 mg Aurobindo Pharma Ltd; Barr Laboratories, Inc; (197-310) (233-794) (217-235) Squibb EC 223 799 997 Bristol-Myers Aurobindo Pharma Ltd.; Barr Laboratories, 250 mg capsules (214-223) (675-874) (613-997) Squibb Inc; Cipla Ltd.; Ranbaxy Ltd.; 288 1267 a 1269 Bristol-Myers Aurobindo Pharma Ltd.; Barr Laboratories; 400 mg (279-288) (507-1302) (1129-1386) Squibb Hetero Drugs Ltd.; Cipla Ltd.; Ranbaxy Ltd.
    [Show full text]
  • Partial List Ex Conference 20
    Artemis Health Institute Bharat Serums & Vaccines Carrier CP Milk & Food Products Discovery FCDO GlaxoSmithkline Henkel India Shelter Finance Corporation Kadtech Infraprojects LSEG MIND NIIT Paytm Money PT Bank BTPN RTI Shyam Spectra Stryker ThoughtWorks ValueMined Technologies Y-Axis Solutions Arth Group Bharti Axa Life Insurance Cars24 CP Plus Dksh FE fundinfo Glenmark Pharmaceuticals Herbalife Nutition IndiaMART Kaivalya Educatiion Foundation LTI MindTickle Nineleaps technology solutions PayU PT. Media Indra Buana Ruby Seven Studios Shyam Spectra STT Global Data Centres Thryve Digital Valuex Technologies Yamaha Motor Arvind Fashions Bhel Caterpillar CP Wholesale DLF Fedex GlobalEdge Here Technologies Indigo Kalpataru Luminous Power Technologies Mindtree Nippon Koei PCCPL PTC Network Rustomjee Sidel Successive Technologies Tierra Agrotech Varroc Engineering Yanbal Asahi India Glass BIC CDK Global CPI DMD ADVOCATES Ferns n Petals GlobalLogic Herman Miller Indmoney Kama Ayurveda Luthra Group MiQ Digital NISA Global PCS Publicis Media S P Setia Siemens Sulzer Pumps Tifc Varuna Group Yanmar TAKE A LOOK AT LIST OF Ashirvad Pipes Bidgely Technologies CEAT Creditas Solutions DP World Ferrero GMR Hero Indofil industries Kanishk Hospital Luxury Personified Mizuho Bank Nissan Peak Infrastructure Management PUMA Group S&P Global Sigma AVIT Infra Services Summit Digitel Infrastructure TIL Vastu Housing Finance Corpora- Yara COMPANIES WHO WILL JOIN Asian paints Bigtree Entertainment Celio Cremica Dr Reddy's Ferring Pharmaceuticals Godrej & Boyce
    [Show full text]
  • Creating a Global Enterprise
    Creating a Global Enterprise ANNUAL REPORT 2005–06 DR. REDDY’S LABORATORIES LIMITED CREATING A GLOBAL ENTERPRISE In the world of matter, a drop of liquid diffuses slowly in another and forms a pattern that it is distinctive, reflective of its nature. Through more than a decade of steady effort and guided by an unswerving original vision, Dr. Reddy’s Laboratories has been growing into a business that has earned the right to be called global. When a business evolves, rather than changes suddenly, its growth is likely to endure. This year’s cover images, as a whole, tell the story of this transformation. The front shows how an enterprise, like a drop of reagent, can take a global shape in its own distinctive way, guided by its inherent nature. The back cover reflects our focus on three continental geographies and in the inside covers are images of diffusion, reflective of our creative energy. CONTENTS DR. REDDY'S LABORATORIES LIMITED chairman’s key creating a global inspired people, letter highlights enterprise — breakthrough Dr. Reddy’s performance transformational journey 004 008 010 020 safety, health & social board of management corporate environment responsibility — directors discussion & governance Dr. Reddy’s analysis Foundation 023 025 028 030 045 additional five years intangible ratio directors’ shareholders‘ at a glance accounting analysis report information 062 073 074 075 076 IGAAP IGAAP U.S.GAAP information on statement standalone consolidated consolidated the financials of pursuant to financials financials financials subsidiary Section 212 companies 087 125 163 202 203 notice of glossary annual general meeting 204 209 chairman’s letter 2005-06 has been a momentous what has happened in 2005-06 — and has transformational year in the history of occurred across various businesses of your your Company.
    [Show full text]
  • Impact of Financial Planning on Financial Performance-A Study of Select Undertakings
    Quest Journals Journal of Research in Business and Management Volume 9 ~ Issue 5 (2021) pp: 88-95 ISSN(Online):2347-3002 www.questjournals.org Research Paper Impact of Financial planning on Financial performance-A study of select undertakings Dr. PasunuriAmaraveni Associate Professor, University College of Commerce & Business Management, Kakatiya University, Warangal, Telangana, (India) MulukalapallySusruth Research scholar, Kakatiya University, Warangal, Telangana (India) ABSTRACT Financial planning is an integral part of financial management which deals with the management of a firm’s funds with a view to maximizing profit and the wealth of shareholders. The main aim of this study is to examine the impact of financial planning on financial performance. The sample used in this study are 5 companies of pharmaceutical industry which listed in National stock exchange and secondary data collected for period 2011- 2020.Regression analysis were employed to analyze the relationship between the dependent variable and independent variables. Findings show that there is a significant relationship between Financial planning and the financial performance with the R2 of 43%,30%,45%,36% and38%. Overall, the financial performance of Alkem laboratories Ltd. is highest with comparison of other companies and lowest is cadila Healthcare Ltd. The study findings indicated that Financial planning had positive impact on the financial performance. The study recommended the pharma companies should invest optimum amount infunding decisions, investment decisions and implementing financial policies with maintaining minimum level of profit as it had positive impact on the financial performance, the least variation to the expected results and that leads to highest contribution to operating profit.The study therefore concludes that sound financial planning by the pharma companies lead to a better financial performance as accountability was enhanced through all levels of decision making.
    [Show full text]
  • S.No. Scrip Name Symbol Series Leverage (In Times) 1 MARICO
    SCRIPS AVAILABLE FOR INTRADAY WITH LEVERAGES PROVIDED ON THEM Leverage Scrip Name Symbol Series (in times) S.No. 1 MARICO LIMITED MARICO 7.61 2 DABUR INDIA LIMITED DABUR 7.92 3 HINDUSTAN UNILEVER LIMITED HINDUNILVR 7.48 4 COLGATE PALMOLIVE (INDIA) LIMITED COLPAL 7.48 5 NESTLE INDIA LIMITED NESTLEIND 7.39 6 Alkem Laboratories Limited ALKEM 6.91 7 TATA CONSULTANCY SERVICES LIMITED TCS 7.24 8 DR. REDDY'S LABORATORIES LIMITED DRREDDY 6.54 9 PIDILITE INDUSTRIES LIMITED PIDILITIND 7.07 10 GODREJ CONSUMER PRODUCTS LIMITED GODREJCP 5.79 11 POWER GRID CORPORATION OF INDIA LIMITED POWERGRID 6.46 12 ACC LIMITED ACC 6.61 13 NTPC LIMITED NTPC 6.64 14 ITC LIMITED ITC 7.05 15 ASIAN PAINTS LIMITED ASIANPAINT 6.52 16 BRITANNIA INDUSTRIES LIMITED BRITANNIA 6.98 17 BERGER PAINTS (I) LIMITED BERGEPAINT 6.78 18 EXIDE INDUSTRIES LIMITED EXIDEIND 6.89 19 HDFC BANK LIMITED HDFCBANK 6.63 20 DIVI'S LABORATORIES LIMITED DIVISLAB 6.69 21 MRF LIMITED MRF 6.73 22 INDIAN OIL CORPORATION LIMITED IOC 6.49 23 BAJAJ AUTO LIMITED BAJAJ-AUTO 6.64 24 SIEMENS LIMITED SIEMENS 6.40 25 THE RAMCO CEMENTS LIMITED RAMCOCEM 6.23 26 TORRENT POWER LIMITED TORNTPOWER 6.10 27 UNITED BREWERIES LIMITED UBL 6.16 28 INFOSYS LIMITED INFY 6.82 29 CIPLA LIMITED CIPLA 6.52 30 Pfizer Limited PFIZER 6.41 31 PETRONET LNG LIMITED PETRONET 6.45 32 UNITED SPIRITS LIMITED MCDOWELL-N 6.24 33 CADILA HEALTHCARE LIMITED CADILAHC 5.97 34 WIPRO LIMITED WIPRO 6.10 35 SUN PHARMACEUTICAL INDUSTRIES LIMITED SUNPHARMA 6.18 36 BATA INDIA LIMITED BATAINDIA 6.44 37 LARSEN & TOUBRO LIMITED LT 6.38 38 ULTRATECH CEMENT
    [Show full text]
  • IN the UNITED STATES DISTRICT COURT for the DISTRICT of DELAWARE ) NOVARTIS PHARMACEUTICALS ) CORPORATION ) ) Plaintiff, ) ) V
    Case 1:18-cv-01043-LPS Document 3 Filed 07/16/18 Page 1 of 4 PageID #: 132 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ) NOVARTIS PHARMACEUTICALS ) CORPORATION ) ) Plaintiff, ) ) v. ) C.A. No. _____ ) ACCORD HEALTHCARE INC., INTAS ) PHARMACEUTICALS LIMITED, ) ALKEM LABORATORIES, LTD., S&B ) PHARMA, INC., AUROBINDO ) PHARMA LIMITED, AUROBINDO ) PHARMA USA, INC., BIOCON ) LIMITED, BIOCON PHARMA, INC.. ) BIONPHARMA INC., BRECKENRIDGE ) PHARMACEUTICAL, INC., ) STANDARD CHEMICAL & ) PHARMACEUTICAL CO., LTD., DR. ) REDDY’S LABORATORIES, INC., DR. ) REDDY’S LABORATORIES, LTD., ) EMCURE PHARMACEUTICALS, ) HERITAGE PHARMACEUTICALS INC., ) EZRA VENTURES, LLC, FIRST TIME ) US GENERICS LLC, GLENMARK ) PHARMACEUTICALS INC., USA, ) GLENMARK PHARMACEUTICALS ) LIMITED, HEC PHARM CO., LTD., HEC ) PHARM GROUP, HEC PHARM USA ) INC., HETERO USA INC, HETERO ) LABS LIMITED UNIT-V, HETERO ) LABS LIMITED, MYLAN ) PHARMACEUTICALS, INC., ) NOSTRUM LABORATORIES INC., ) NOSTRUM PHARMACEUTICALS, ) LLC, MSN LABORATORIES PRIVATE ) LIMITED, MSN PHARMACEUTICALS ) INC., PAR PHARMACEUTICAL INC., ) PRINSTON PHARMACEUTICAL INC., ) STRIDES GLOBAL PHARMA PRIVATE ) LIMITED, STRIDES PHARMA, INC., ) TORRENT PHARMA INC., TORRENT ) PHARMACEUTICALS LTD., ZYDUS ) PHARMACEUTICALS (USA) INC., and ) CADILA HEALTHCARE LIMITED ) ) Defendants. ME1 27645531v.1 Case 1:18-cv-01043-LPS Document 3 Filed 07/16/18 Page 2 of 4 PageID #: 133 SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING AN ABBREVIATED NEW DRUG APPLICATION (ANDA) Plaintiffs hereby provide the information below with respect to the deadlines set forth in 21 U.S.C. § 355(j): Date Patentee(s) Received Notice: See attached chart Date of Expiration of Patent: 9,187,405 (June 25, 2027) Thirty Month Stay Deadline: N/A Dated: July 16, 2018 McCARTER & ENGLISH, LLP By: /s/ Daniel M. Silver Michael P.
    [Show full text]
  • NSE Symbol NSE 6 Month Avg Total Market
    Average Market Cap of 200 listed companies on BSE & NSE for the six months ended 30 June 2021 BSE 6 month Avg NSE 6 month Avg Average of BSE and NSE 6 Total Market Cap Total Market Cap month Avg Total Market Cap S.No. Company Name ISIN BSE SYMBOL (Rs. In Crs.) NSE Symbol (Rs. In Crs.) (Rs. in Crs.) 1 Reliance Industries Ltd INE002A01018 RELIANCE 1338017.01 RELIANCE 1355067.509 1346542.26 Tata Consultancy Services 2 Ltd. INE467B01029 TCS 1169783.56 TCS 1173068.166 1171425.86 3 HDFC Bank Ltd. INE040A01034 HDFCBANK 819037.95 HDFCBANK 818713.671 818875.81 4 Infosys Ltd INE009A01021 INFY 579784.19 INFY 579697.3885 579740.79 5 Hindustan Unilever Ltd., INE030A01027 HINDUNILVR 549336.78 HINDUNILVR 549358.908 549347.84 Housing Development 6 Finance Corp.Lt INE001A01036 HDFC 462288.58 HDFC 461373.1089 461830.84 7 ICICI Bank Ltd. INE090A01021 ICICIBANK 416645.51 ICICIBANK 416389.0234 416517.27 8 Kotak Mahindra Bank Ltd. INE237A01028 KOTAKBANK 361640.52 KOTAKBANK 361438.6361 361539.58 9 State Bank Of India, INE062A01020 SBIN 329767.32 SBIN 329789.268 329778.29 10 Bajaj Finance Limited INE296A01024 BAJFINANCE 324996.53 BAJFINANCE 324843.5005 324920.02 11 Bharti Airtel Ltd. INE397D01024 BHARTIARTL 299981.36 BHARTIARTL 299955.7729 299968.57 12 HCL Technologies Ltd INE860A01027 HCLTECH 261400.46 HCLTECH 261392.0109 261396.24 13 Wipro Ltd., INE075A01022 WIPRO 258617.45 WIPRO 261102.3994 259859.92 14 ITC Ltd INE154A01025 ITC 259423.16 ITC 259396.0648 259409.61 15 Asian Paints Ltd. INE021A01026 ASIANPAINT 253487.28 ASIANPAINT 253454.4536 253470.87 16 AXIS Bank Ltd.
    [Show full text]
  • Strong Expanding to Newer Ones
    2015-16 ANNUAL REPORT Strong in Our Core Market Expanding to Newer Ones Contents Corporate Overview Financial Statements 02 Alkem at a Glance Standalone 04 Global Presence 94 Independent Auditor’s Report 06 Key Therapeutic Areas and Brands in Domestic Market 100 Balance Sheet 08 Chairman’s Message 101 Statement of Profit and Loss 09 Executive Chairman’s Message 102 Cash Flow Statement 10 CEO’s Message 104 Notes 12 Key Financial Highlights 14 Strong Brand Building Capabilities Consolidated 16 Strong Manufacturing and R&D Capabilities 140 Independent Auditor’s Report 18 Extensive Sales Network and Distribution Infrastructure 144 Balance Sheet 20 Growing International Business 145 Statement of Profit and Loss 22 The People Edge 146 Cash Flow Statement 24 Board of Directors 148 Notes 26 Awards and Accolades 197 Notice Statutory Reports Proxy Form 28 Management Discussion and Analysis 48 Directors’ Report 79 Corporate Governance Report Earnings per Net Revenue EBITDA PAT share ` 49,915 ` 8,482 ` 6,731 ` 56.3 million million million Strong in Our Core Market. Expanding to Newer Ones. Growth and consolidation are business imperatives that are achieved as a result of conscious and persistent strategy. More often than not, companies that are able to step out of their comfort zone while retaining their hold over captive markets are the ones that succeed in the long-term. We believe that the path to value-creation is twofold. On the one hand, we continue to focus on consolidating our presence in India and introducing newer products consistently, while improving the breadth and depth of our reach.
    [Show full text]
  • Alkem Laboratories Ltd
    Name of the issue: Alkem Laboratories Ltd 1 Type of issue (IPO/ FPO) IPO 2 Issue size (Rs crore) 1347.7* * Source: Basis of Allotment - pursuant to spill over of undersubscription in Employee category to Net Offer 3 Grade of issue alongwith name of the rating agency Not applicable 4 Subscription level (number of times). If the issue was undersubscribed, please clarify how the funds were 30.8708* Figure is before technical rejections and after adjusting for cheque return cases arranged. *Source: Basis of Allotment 5 QIB holding (as a % of total outstanding capital) as disclosed to stock exchanges (See Clause 35 of the listing agreement) (i) allotment in the issue 5.3 Source: Minutes for basis of allotment dated 19 Dec 2015 (ii) at the end of the 1st Quarter immediately after the listing Source: BSE Filings of the issue (December 31, 2015) 6.04 (iii) at the end of 1st FY (March 31, 2016) 6.81 Source: BSE Filings (iv) at the end of 2nd FY (March 31, 2017) 6.75 Source: BSE Filings (v) at the end of 3rd FY (March 31, 2018) 6.92 Source: BSE Filings 6 Financials of the issuer (as per the annual financial results submitted to stock exchanges under Clause 41 of the listing agreement) As per the annual Consolidated financial results submitted to stock exchanges (Rs. in crores) 1st FY 2nd FY 3rd FY Parameters (March 31, 2016) (March 31, 2017) (March 31, 2018) 1 Income from operations 4,992 5,853 6,431 2 Net Profit for the period 673.12 869.12 611.87 Paid-up equity share capital 23.91 23.91 23.91 Reserves excluding revaluation reserves 3,478.74 4,443.73 4,839.86 Source: Alkem BSE Filings.
    [Show full text]
  • Alkem Laboratories Ltd. BUY
    Alkem Laboratories Ltd. BUY Target Price ₹ 2,306 CMP ₹ 1,698 FY22E PE 20X Index Details The acute therapy segment, in which Alkem is a market leader, is Sensex 38,730 seeing a significant slowdown. In order to fortify its growth and Nifty 11,641 maintain market leadership Alkem has strategized to diversify its revenue stream by foraying into the fast-growing chronic therapy Industry Pharma segment for the domestic markets and developing generic solutions for the world’s largest pharma market namely the US. Scrip Details MktCap (`cr) 20,302.0 Over the last four years Alkem has been working on building capabilities in the direction of its intended strategy. Till date the BVPS (`) 416.9 company has invested ~ Rs. 900 crores in building manufacturing O/s Shares (Cr) 12.0 facilities and R&D activities for filing 120 ANDAs for the US AvVol (Lacs) 10.7 geography. Going ahead we expect revenues to grow at 13% CAGR to Rs 10,309 crores by FY22. EBIDTA and net earnings are expected to 52 Week H/L 2,265/1,693 grow to Rs. 1,856 crores and Rs. 1,398 crores respectively over the Div Yield (%) 0.7 same period. We expect the company to become virtually net debt free FVPS (`) 2.0 by FY22. As a result, return ratios ROE & ROCE are also expected to improve by 220 bps and 60 bps to 15.3% & 19.7% respectively by FY22. Shareholding Pattern Shareholders % We initiate with a BUY for a price target of Rs. 2,306 representing an Promoters 66.0 upside of 36% over 36 months from the CMP of Rs.
    [Show full text]
  • FTSE India 30/18 Capped
    2 FTSE Russell Publications 19 August 2021 FTSE India 30/18 Capped Indicative Index Weight Data as at Closing on 30 June 2021 Constituent Index weight (%) Country Constituent Index weight (%) Country Constituent Index weight (%) Country 3M India 0.1 INDIA Glenmark Pharmaceuticals 0.14 INDIA Oil India Ltd 0.07 INDIA ABB India 0.13 INDIA GMR Infrastructure 0.1 INDIA Oracle Financial Services Software 0.12 INDIA ACC 0.24 INDIA Godrej Consumer Products 0.45 INDIA Page Industries 0.24 INDIA Adani Enterprises 0.57 INDIA Godrej Industries 0.07 INDIA Petronet LNG 0.24 INDIA Adani Gas 0.4 INDIA Godrej Properties 0.18 INDIA PI Industries 0.3 INDIA Adani Green Energy 0.63 INDIA Grasim Industries 0.82 INDIA Pidilite Industries 0.47 INDIA Adani Ports and Special Economic Zone 0.77 INDIA Gujarat Gas 0.19 INDIA Piramal Enterprises 0.41 INDIA Adani Power 0.15 INDIA Havells India 0.34 INDIA Power Finance 0.21 INDIA Aditya Birla Capital 0.08 INDIA HCL Technologies 1.52 INDIA Power Grid Corp of India 0.78 INDIA Alkem Laboratories 0.11 INDIA HDFC Asset Management 0.27 INDIA Punjab National Bank 0.06 INDIA Ambuja Cements 0.33 INDIA HDFC Life Insurance Company 0.63 INDIA Rajesh Exports 0.11 INDIA Apollo Hospitals Enterprise 0.51 INDIA Hero MotoCorp 0.54 INDIA RBL Bank 0.13 INDIA Ashok Leyland 0.25 INDIA Hindalco 0.75 INDIA REC 0.2 INDIA Asian Paints 1.92 INDIA Hindustan Aeronautics 0.05 INDIA Reliance Industries 9.35 INDIA Astral 0.25 INDIA Hindustan Petroleum 0.3 INDIA Reliance Industries - Partly Paid 0.36 INDIA AU Small Finance Bank 0.23 INDIA Hindustan
    [Show full text]